Purpose To determine whether associations between estrogen pathway-related single nucleotide polymorphisms (SNPs) and breast cancer risk differ by molecular subtype, we evaluated associations between SNPs in cytochrome P450 family 19 subfamily A polypeptide 1 (CYP19A1), estrogen receptor (ESR1), 3-beta hydroxysteroid dehydrogenase type I (HSD3B1), 17-beta hydroxysteroid dehydrogenase type II (HSD17B2), progesterone receptor (PGR), and sex hormone-binding globulin (SHBG) and breast cancer risk in a case-control study in North Carolina. Methods Cases (n = 1,972) were women 20-74 years old and diagnosed with breast cancer between 1993 and 2001. Population-based controls (n = 1,776) were frequency matched to cases by age and race. A total of 195 SNPs were genotyped, and linkage disequilibrium was evaluated using the r 2 statistic. Odds ratios (ORs) and 95 % confidence intervals (CIs) for associations with breast cancer overall and by molecular subtype were estimated using logistic regression. Monte Carlo methods were used to control for multiple comparisons; two-sided p values \3.3 9 10 -4 were statistically significant. Heterogeneity tests comparing the two most common subtypes, luminal A (n = 679) and basal-like (n = 200), were based on the Wald statistic. Results ESR1 rs6914211 (AA vs. AT?TT, OR 2.24, 95 % CI 1.51-3.33), ESR1 rs985191 (CC vs. AA, OR 2.11, 95 % CI 1.43-3.13), and PGR rs1824128 (TT?GT vs. GG, OR 1.33, 95 % CI 1.14-1.55) were associated with risk after accounting for multiple comparisons. Rs6914211 and rs985191 were in strong linkage disequilibrium among controls (African-Americans r 2 = 0.70; whites r 2 = 0.95). There was no evidence of heterogeneity between luminal A and basal-like subtypes, and the three SNPs were also Robert C. Millikan: Deceased.
Introduction
Breast cancer can be classified into molecular subtypes that differ with respect to biology, survival, and some risk factors [1] [2] [3] [4] [5] [6] . Although more than 70 single nucleotide polymorphisms (SNPs) have been associated with breast cancer risk [7, 8] , there have been few investigations of genetic variation and risk of specific breast tumor molecular subtypes. A pooled analysis examined 10 risk loci and demonstrated heterogeneity of risk associations by subtype [9] . More recently, the Carolina Breast Cancer Study (CBCS) demonstrated that subtype associations for 78 SNPs in several susceptibility pathways varied by tumor subtype [10] . Beyond these two studies, information regarding the heterogeneity of association between genetic variants and risk of breast cancer subtypes is limited. Greater understanding of the relationship between genetic polymorphisms and specific tumor types may provide clues regarding which biological mechanisms are involved in the tumorigenesis of different subtypes.
Estrogen and progesterone-related genes are likely candidates for harboring breast cancer risk variants due to the central role that estrogen and progesterone play in normal breast development and breast cancer [11] [12] [13] and may provide clues as to how the estrogen pathway functions in tumors. Estrogen bound to the estrogen receptor (ER), encoded by ESR1, can act as a transcription factor for genes associated with cell proliferation and survival, including growth factors, tumor suppressors, and proapoptotic genes [14] . Progesterone signaling via the progesterone receptor (PR), encoded by PGR, also influences transcription and can act through multiple pathways to stimulate proliferation [15, 16] .
Previous analyses of the relationship between nongenetic risk factors and breast cancer subtypes in the CBCS indicate that there may be etiologic heterogeneity between breast cancer subtypes [4] . Millikan et al. [4] previously reported that associations for some reproductive risk factors were qualitatively different between luminal A breast cancers, which are defined in part by ER and/or PR expression, and basal-like breast cancers, which are defined in part by lack of ER and PR expression. Specifically, parity (vs. nulliparity) was inversely associated with luminal A breast cancer regardless of breastfeeding status, whereas parity in women who breastfed was unassociated with the basal-like subtype, and parity in women who did not breastfeed was positively associated with basal-like breast cancer [4] . Additionally, earlier age at first birth was associated with a lower risk of luminal A, but increased risk of basal-like breast cancer [4] . The fact that these differences were observed among reproductive risk factors suggests that this heterogeneity may have a hormonal link.
We hypothesized that hormonal factors related to parity and lactation might influence pathways leading to luminal A and basal-like breast cancer in different ways and that some of these differences may be rooted in genetic variation. Therefore, we examined associations between SNPs in six genes related to the production, bioavailability, and signaling of estrogen and progesterone and breast cancer risk. In addition to ESR1 and PGR, we examined genes for cytochrome P450 family 19 subfamily A polypeptide 1 (CYP19A1), which converts androgens to estrogens [17] ; 17-beta hydroxysteroid dehydrogenase type II (HSD17B2), which oxidizes active sex steroids into inactive precursors, including conversion of estradiol into estrone [18] ; sex hormone-binding globulin (SHBG), which binds estrogen in the blood controlling its availability to bind to ER [19, 20] ; and 3-beta hydroxysteroid dehydrogenase type I (HSD3B1), which converts pregnolone to progesterone [17, 21] . Associations were estimated for breast cancer risk overall and for breast cancer molecular subtypes. This investigation was informed by previous findings of nongenetic risk factor heterogeneity between luminal A and basal-like subtypes [4] , therefore we focused subtype-specific genetic risk factor comparisons primarily on luminal A and basal-like tumors.
Materials and methods

Study population
The CBCS is a population-based case-control study of breast cancer in North Carolina and has been described previously [22, 23] . Briefly, eligible cases included women 20-74 years old who were diagnosed with primary invasive breast cancer from 1993 to 2001 and lived within the 24-county study area at diagnosis. Women diagnosed with breast carcinoma in situ (CIS) were also enrolled from 1996 to 2001. Cases were identified through the North Carolina Central Cancer Registry using rapid case ascertainment. Randomized recruitment was used to oversample invasive cases that were African-American or \50 years old [24] . Eligible controls included women 20-74 years old who lived within the study area and had no personal history of breast cancer. Controls were identified through Department of Motor Vehicles (\65 years old) or Health Care Financing Administration (C65 years old) records and were frequency matched to cases by race and 5-year age groups. Case and control response rates were 76 and 55 % with respect to invasive case recruitment, and 83 and 65 % for CIS recruitment.
A total of 2,311 cases and 2,022 controls provided informed consent and were interviewed about breast cancer risk factors, including reproductive and menstrual history, exogenous hormone use, and family history of cancer. A total of 2,045 (88 %) cases and 1,818 (90 %) controls also provided a blood sample. DNA was extracted from blood and stored at -80°C. This study was approved by the University of North Carolina at Chapel Hill Institutional Review Board.
Molecular subtype
Breast tumor molecular subtype was determined by immunohistochemical analysis of ER, PR, epidermal growth factor receptor (EGFR), c-erb B2/neu (HER2), and cytokeratin 5/6 (CK 5/6), using methods described previously [4, [25] [26] [27] [28] . Tumor tissue was available for 1,845 of 2,311 cases, and immunohistochemistry was completed for 1,424. Cases where molecular subtype was determined were more likely to be African-American and have later stage at diagnosis than cases where subtype data were incomplete, but did not differ by other characteristics [4] . Tumors were classified as luminal A (ER? and/or PR?, HER2-); basal-like (ER-, PR-, HER2-, CK5/6? and/or EGFR?); luminal B (ER? and/or PR?, HER2?); HER2?/ER-(ER-, PR-, HER2?); and unclassified (ER-, PR-, HER2-, CK5/6-, EGFR-).
SNP selection
Tag SNPs for ESR1, HSD3B1, HSD17B2, PGR, and SHBG were selected from International HapMap Project CEU (European) and YRI (West African) population data [29] using Haploview Tagger software [30] [31] [32] ; data from the HapMap African-American population were unavailable at the time of SNP selection. A minimum pairwise r 2 of 0.80 was used to define tags within the genomic regions specified in Table 1 . Selection was restricted to SNPs with a minimum minor allele frequency of 0.10. SNPs selected from each population were combined into a single list. CYP19A1 SNPs were selected from a published list of linkage disequilibrium (LD) block tag SNPs in AfricanAmerican and white women [33, 34] . We also included 14 SNPs, identified through a literature search, which had been investigated previously for an association with breast cancer risk or a functional effect (Table 1 ). In total, 207 SNPs were selected for study.
Genotyping
SNPs were genotyped at the University of North Carolina Mammalian Genotyping Core using the Illumina GoldenGate assay (Illumina, Inc., San Diego, CA, USA) as part of a 1,536-SNP panel. Panel results and quality control measures were reported in detail previously [35] . Exact tests for deviation from Hardy-Weinberg equilibrium were conducted among controls, stratified by self-identified race [36] . Genotyping cluster images were re-reviewed for SNPs with Hardy-Weinberg test p values \0.01; all SNPs reviewed during this process had good signal intensity and none were excluded. A total of 195 of the 207 (94 %) selected SNPs had acceptable data and were included in this analysis (Table 1) . Additionally, ancestry informative markers (AIMs) specifically selected to maximize the differences between African and European ancestral populations based on differences in allele frequencies and Fisher's information content were genotyped for each participant [35, 37] . A total of 144 of 158 AIMs passed quality control and were used in the analysis.
A total of 2,039 cases and 1,818 controls had DNA available for genotyping. Subjects were excluded from analysis if there were genotype calls for \95 % of SNPs (n = 103), genotype-determined sex was male (n = 5), or there was suspected contamination (n = 1), resulting in data for 1,972 cases and 1,776 controls (Online Resource 1). Subjects without genotype data were more likely to be cases, recruited after 1996, or African-American, but did not differ by other risk factors or molecular subtype (among cases). A total of 1,220 cases had both genotype and molecular subtype data (luminal A, n = 679; basallike, n = 200, luminal B, n = 116; HER2?/ER-, n = 94; unclassified, n = 131).
Covariates
Age was defined as age in years at breast cancer diagnosis (cases) or recruitment (controls). Self-identified race was reported during the study interview. Less than 2 % of participants were Native American/Eskimo, Asian/Pacific Islander, Hispanic, or mixed race and were grouped with white women as non-African-American. Self-identified race was missing for two participants, who were excluded from analysis. Proportion of African or European ancestry was estimated from 144 AIMs using maximum likelihood estimation, based on the observed allele frequencies in the study population, the contributions from the ancestral populations, and the differences in allele frequency between the ancestral populations [37] [38] [39] . Methods assumed two ancestral populations (European and African), such that the proportion of African ancestry was equal to 1 minus the proportion of European ancestry. Estimates of African ancestry were included in regression models as a proportion ranging from 0 to 0.96 (the maximum observed value).
Statistical analysis
Genotype frequencies for each SNP were calculated stratified by self-identified race and adjusted for the sampling probabilities used to select participants. LD between SNPs was estimated by calculating pairwise r 2 in Haploview according to self-identified race and case status [30] . Odds ratios (ORs) and 95 % confidence intervals (CIs) for the association between genotypes and overall breast cancer risk were estimated using unconditional binary logistic regression in SAS v9.1 (SAS, Cary, NC, USA). Subtypespecific associations were estimated using unconditional polytomous logistic regression. Genotype associations were modeled using the general statistical model (2 degrees of freedom). If the number of participants homozygous for the rare allele was \5 cases, \5 controls, or \10 cases and 10 controls, the rare homozygote and heterozygote groups were combined. Furthermore, if the results indicated that the underlying genetic model was recessive, dominant, or additive, additional analyses specific to that model were conducted. The Wald test was used to evaluate heterogeneity of basal-like and luminal A regression coefficients from the polytomous logistic regression model. The null hypothesis was that the coefficients were equal for the two subtypes. Additionally, we conducted exploratory analyses examining associations with luminal B, HER2?/ER-, and unclassified subtypes and estimating race-stratified subtype associations. In order to evaluate the effect of including CIS cases in the analysis, we re-evaluated associations excluding CIS study participants.
All statistical tests were two sided. Monte Carlo methods were used to approximate the joint distribution of test statistics and evaluate the family wise error rate to control for multiple comparisons, insuring that correlation among SNPs did not result in an overly conservative correction [40] . The nominal alpha level indicating statistical significance for genotype associations was 0.05; the Monte Carlo-adjusted level was 3.3 9 10 -4 . All models were adjusted for the frequency-matching factors (age and self-identified race) and the proportion of African ancestry in order to control for residual population stratification. Models also included an offset term in order to account for the randomized recruitment case-sampling (33, 34) strategy and to produce population-based effect estimates [24, 41] . Associations between rs1824128 and the luminal A and basal-like subtypes were weaker than the association with breast cancer overall, and there was no evidence of heterogeneity between the subtypes (p = 0.80; Table 2 ). Rs1824128 was in strong LD with PGR rs11224575 among all subjects, and in moderate LD with PGR rs11224579, among white cases and controls (Online Resource 4); rs11224575 and rs11224579 were positively, but not significantly, associated with breast cancer risk (Online Resource 3). All associations remained similar after the exclusion of CIS study participants (data not shown).
Results
Of
To determine whether the rs6914211, rs985191, and rs1824128 associations were consistent across other tumor types, we examined their associations with HER2?/ER-, luminal B, and unclassified subtypes. The direction of association was consistent with what was seen for breast cancer overall, with the exception that rs1824128 was not associated with the luminal B subtype (Online Resource 5). Associations between rs6914211 and rs985191 and luminal B breast cancer were particularly strong. For each, two copies of the risk allele were associated with an approximately fivefold increase in luminal B risk (rs6914211 AA vs. AT?TT, OR 4.96, 95 % CI 2.37-10.38; rs985191 CC vs. AA, OR 5.12, 95 % CI 2.41-10.86). With the exception of the previously mentioned luminal B associations with rs6914211, rs985191, and rs9397463, no other SNPs were significantly associated with luminal B, HER2?/ER-, or unclassified tumors after accounting for multiple comparisons. When we explored whether subtype-specific associations for these SNPs differed by self-identified race, we found that the association between PGR rs1824128 and risk was stronger among African-Americans than non-AfricanAmericans for all subtypes except the unclassified tumors. However, these associations were imprecise due to the small number of cases in some subgroups (Online resource 6) .
No suspected functional SNPs met our Monte Carloadjusted criteria for an association with risk; however, CYP19A1 rs700519 was associated with a reduced risk of breast cancer overall at the nominal significance level of 0.05 (TT vs. CC, OR 0.44, 95 % CI 0.21-0.89; Table 3 ). An inverse association was also noted for luminal A and basal-like subtypes, although the luminal A association was slightly weaker than the overall association.
Discussion
We investigated the association between SNPs in CYP19A1, ESR1, HSD3B1, HSD17B2, PGR, and SHBG and breast cancer risk and identified two SNPs in ESR1 and one in PGR that were associated with breast cancer risk. There was no association between HSD3B1, HSD17B2, or SHBG variants and risk. Statistical significance criteria were adjusted for the effective number of comparisons made, but it is still possible that some of the significant associations we observed were due to chance.
An increasing number of studies have evaluated heterogeneity of SNP associations by tumor characteristics, including ER, PR, and HER2 and other clinical characteristics [42] [43] [44] [45] [46] [47] [48] [49] , but few have considered intrinsic molecular subtype, which defines basal-like breast cancer as a specific type of ER-negative breast cancer. Studies that have evaluated molecular subtypes have shown that genetic associations [9, 10] and gene expression levels [50] differ by molecular subtype for some risk alleles. Although variants in estrogen and progesterone signaling pathwayrelated genes have been investigated previously for associations with overall breast cancer risk, we examined associations between these variants and luminal A and basal-like breast cancer subtypes because subtype differences in hormonally related non-genetic risk factors and differences in ER and PR expression suggested that genetic risks related to hormonal pathways may differ between these subtypes as well. However, in this study, associations with genetic variants in estrogen and progesterone pathway genes were largely similar for the luminal A and basal-like subtypes. Although case numbers were small, positive associations for rs6914211, rs985191, and rs1824128 were generally consistent for luminal B, HER2?/ER-, and unclassified tumors as well. ESR1 rs6914211 and rs985191 were associated with breast cancer risk in this study. Previously, in a large pooled analysis, rs985191 was found to be positively, but not significantly associated with breast cancer risk [51] ; to our knowledge, no previous studies have identified rs6914211 as having an association with risk. Rs6914211 and rs985191 are located close to other risk-associated regions on chromosome 6. ESR1 rs3020314 and ESR1 rs3020401 were identified as potentially associated with risk in a two-stage candidate SNP analysis [52] , and rs3020314 was associated with ER-positive breast cancer in a three-stage study of ESR1 tag SNPs [51] . Rs3020314 and rs3020401 were in low to moderate LD with rs6914211 and rs985191 among white CBCS participants (r 2 ranging from 0.28 to 0.32). In this study, rs3020401 was positively associated with risk of all subtypes except for HER2?/ ER-, but at levels below our criteria accounting for multiple comparisons, whereas rs3020314 was not associated with overall or subtype-specific risk. It is possible that rs3020314/rs3020401 and rs6914211/rs985191 are reflecting associations related to the same causal locus and inconsistencies between studies may be a result of regional variation in LD between study populations. Fine-mapping of this region may help illuminate the nature of the causal locus (or loci) that may be near these SNPs.
In addition to these tag SNP associations, genome wide association studies (GWAS) have also identified breast cancer risk loci on 6q25.1: one within ESR1 [46] and two [60 Kb upstream of ESR1 [53, 54] . The upstream SNPs are in close proximity to C6ORF97 and C6ORF211, genes of unknown function whose expression is highly correlated with ESR1 expression [55] . These GWAS risk variants were not genotyped in this analysis; however, future investigations of 6q25.1 should consider joint analyses of regions within and upstream of ESR1, as the co-expression profiles suggest a biological relationship.
PGR intronic SNP rs1824128 was also associated with breast cancer risk. To our knowledge, previous studies have not identified rs1824128 as associated with risk nor has 11q22.1 been identified as a harboring risk loci in breast cancer GWAS. Much of the investigation into PGR variants and breast cancer risk has focused on the functional polymorphism ?331 G/A (rs10895068), which was not associated with risk in this study or a recent meta-analysis [56] . Thus, replication of the rs1824128 association is necessary before the meaning of this association can be assessed.
Our analysis of potentially functional SNPs suggested an inverse association between the CYP19A1 rs700519 (R264C) TT genotype and risk of breast cancer overall. Although this association did not meet the multiple comparison-adjusted criteria for statistical significance, there is prior evidence that the R264C change may be associated with risk. Some have reported that 264C results in reduced hydrophobicity, reduced CYP19A1 expression, and lower aromatase activity [57, 58] ; lower aromatase activity would be consistent with the association between the TT genotype and lower breast cancer risk in the CBCS. However, another study reported no difference in enzymatic activity between 264R and 264C [59] , and rs700519 was not associated with risk in other epidemiologic studies [33, 60, 61] . The rs700519 TT genotype is uncommon and was rare in CBCS non-African-American participants. A lack of association with breast cancer risk in previous studies may be explained by the low prevalence of the at-risk genotype in populations of non-African descent.
Molecular subtype data were not available for all enrolled cases; however, genotype distributions only differed between cases with and without molecular subtype data for four SNPs (HSD17B2 rs3111351 and rs8191136 in African-Americans, and ESR1 rs6557177 and rs985695 in non-African-Americans). This is within the number expected to differ due to chance alone, suggesting that results were likely not biased due to the inability to include all cases in subtype-specific analyses. Other limitations of this analysis included low SNP density in some genes and limited statistical power for identifying subtype heterogeneity. The SNP selection method we employed selected SNPs based on LD with other SNPs (i.e., tag SNPs), such that a single SNP may be a marker for other correlated SNPs. This tagging method has been shown to provide efficient coverage of gene regions [32] ; however, failure of tag SNPs during genotyping may have led to low coverage in some areas. The number of basal-like cases was relatively low in comparison with the number of luminal A cases, and heterogeneity tests may have lacked power. However, visual comparison of ORs for the three SNPs most strongly associated with overall risk shows similar associations luminal A and basal-like subtypes with the same direction of effect; thus it is unlikely that any meaningful heterogeneity was overlooked for these particular SNPs.
The major strength of this analysis was the ability to examine molecular subtypes in a large, population-based study. These IHC-determined subtypes have unique risk factor profiles and are related to breast cancer prognosis [4, 5, 25] , but the contribution of genetic susceptibility to the risk of each subtype has not yet been determined. Our ability to detect statistical differences between luminal A and basal-like associations was limited, but our results show clear positive associations between the three risk SNPs and basal-like and luminal A breast cancers, as well as luminal B, HER2?/ER-, and unclassified subtypes. These data suggest that genetic variants in pathways primarily related to hormonal mechanisms may be important factors for ER-negative as well as ER-positive subtypes. We can only speculate as to why differences in association by molecular subtype were not observed. One possible explanation is that heterogeneity may be related to polymorphisms in hormonally related genes not evaluated in this study. We evaluated six genes, but there are several other hormonally related candidate genes that may be differentially related to risk of breast cancer subtypes. Another possibility is that the non-genetic risk factor heterogeneity observed may be related to aspects of parity and lactation that are not directly related to sex hormones.
Further investigation of the relationship between hormonal and non-hormonal biomarkers and risk of breast cancer subtypes is needed to understand the relative contributions of each biological pathway.
Another strength was that African-American participants were oversampled, providing an opportunity for exploratory analyses of molecular subtype risk stratified by self-identified race. Despite recent efforts to conduct largescale studies of genetic variation and breast cancer risk in African-Americans, most early genetic susceptibility studies have consisted primarily of women of European descent. We explored associations stratified by self-identified race with the hypothesis that there may be riskassociated variants that are more prevalent in African or African-American populations. This may include variants associated with risk of basal-like breast cancer, a subtype that is more prevalent among African-Americans [4] . Furthermore, because LD range can differ between populations of African as compared with European descent [62, 63] , it is possible that a tag SNP may have different levels of correlation with causal loci in different populations. Thus, a SNP may be associated with risk among subjects with one genetic background and weakly or not associated among subjects with another. In this population, CYP19A1 R264C was more prevalent among African-Americans and associations with PGR rs1824128 were stronger among African-Americans, an observation that was largely consistent across subtypes but was based on small numbers and must be interpreted with caution.
Genotype frequencies for rs1824128 were similar comparing African-American and non-African-American participants and so differing prevalence of the risk allele is not a fitting explanation for why the rs1824128 association might be limited to African-Americans. As mentioned previously, there is no data pointing to any functional effect associated with rs1824128 and the association requires replication in order to be confirmed. It is possible that the observed differences by race were due to chance. In an analysis of GWAS-identified and candidate gene SNPs, O'Brien et al. [10] found that molecular subtypespecific associations differed between African-Americans and non-African-Americans for a minority of SNPs they examined; however, that study was also carried out within the CBCS and was subject to the same power limitations that we experienced in this study. Future analyses intended to focus primarily on racial differences in risk of breast cancer subtypes will require even larger case numbers and would be most efficiently carried out through pooled analyses. Finally, all statistical models were adjusted for the proportion of African ancestry, controlling for potential confounding due to population stratification.
In conclusion, this analysis identified genetic variants in ESR1, PGR, and CYP19A1 that were associated with breast cancer risk, and there was little evidence of heterogeneity between luminal A and basal-like subtypes. Associations in ESR1 and CYP19A1 were consistent with data from other studies. Further characterization of the effects of these SNPs or related loci on gene expression could increase our understanding of the biological pathways active in breast carcinogenesis.
